Aspen Lamzid

Quick links

Choose a section

Quick links to important sections

Advertisements

Aspen Lamzid

Advertisements
Advertisements

Treatment option: Immunodeficiency, Infection

Advertisements

Overview of Aspen Lamzid

What is Aspen Lamzid?

Aspen Lamzid is a fixed-dose combination antiretroviral medication used in the management of human immunodeficiency virus (HIV) infection. It contains two active pharmaceutical ingredients that belong to the class of medications known as nucleoside reverse transcriptase inhibitors (NRTIs):

  • Lamivudine (150 mg)
  • Zidovudine (300 mg)

Mechanism of Action

Both components of the medication work by interfering with the action of an enzyme called reverse transcriptase. HIV requires this enzyme to replicate its genetic material and spread within the body. By inhibiting this process, the medication helps to reduce the viral load in the blood and can assist in increasing the count of CD4 cells, which are vital for a healthy immune system.

Clinical Purpose

The primary objective of this treatment is to slow the progression of HIV infection and reduce the risk of associated complications. It is typically used as part of a broader antiretroviral therapy (ART) regimen. Combining two different NRTIs into a single tablet is intended to simplify treatment schedules and support consistent medication adherence.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed entry
Advertisements

What side effects are possible with Aspen Lamzid?

Aspen Lamzid, a fixed-dose combination of Lamivudine and Zidovudine, has an officially documented safety profile structured by regulatory agencies based on incidence and physiological impact.

Documented Serious Adverse Reactions

The label highlights several serious adverse reactions. These include the risk of Lactic Acidosis and Severe Hepatomegaly with Steatosis, a rare but potentially fatal metabolic condition that may occur after several months of treatment. Hematologic Toxicity, such as severe Anemia and Neutropenia, is another primary concern, particularly in individuals with advanced HIV disease. Symptomatic Myopathy (muscle disease) is associated with the prolonged use of zidovudine. Additionally, co-infected patients who discontinue treatment face the risk of Acute Exacerbations of Hepatitis B.

Frequency and System Classifications

Adverse reactions are classified by frequency according to regulatory standards. Very common (ge 1/10) effects include headache, nausea, malaise and fatigue, and diarrhea. Common effects (ge 1/100 to < 1/10) include further blood disorders like neutropenia and anemia, and respiratory symptoms like cough. Effects are grouped by System-Organ Class, with prominent involvement in the Blood and Lymphatic System, Gastrointestinal Disorders, and Metabolism (e.g., Lipoatrophy or fat loss).

Population-Specific Limitations

Due to the fixed-dose format, regulatory documents note that the medication is not recommended for patients with significant Renal or Hepatic Impairment or for pediatric patients weighing less than 30 kg, as dose adjustment is not possible. The fixed-dose formulation also imposes safety constraints, such as increasing the risk of Hematologic Toxicity if co-administered with other bone marrow suppressive agents. The onset of Immune Reconstitution Inflammatory Syndrome (IRIS) is typically observed within the first few weeks or months following the start of therapy.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Aspen Lamzid is a fixed-dose combination product containing lamivudine and zidovudine. Information on overdose is consistent with the known effects of its active components. An overdosage is considered a serious event, and immediate medical attention is required upon the presentation of any associated signs or symptoms.

Overdose manifestations are generally extensions of the drug's known adverse reaction profile, primarily affecting the hematologic and gastrointestinal systems.


Overdose Presentation and Response
Documented Manifestations: Symptoms may include those associated with severe hematologic toxicity, such as neutropenia and anemia (e.g., unusual tiredness, weakness, fever, chills, pale skin), as well as gastrointestinal distress (nausea, vomiting). In rare instances, overdosage may be associated with more severe, life-threatening complications such as lactic acidosis or severe hepatotoxicity.
Associated Risk Factors: Particular circumstances that may lead to an increased risk of overexposure include improper dose calculation, especially in children, and failure to adjust the dose in patients with severe renal impairment.
Emergency Action Required: If you suspect an overdose, you must contact emergency medical services or a poison control center right away, or proceed immediately to the nearest hospital emergency room. Management typically involves general supportive care and monitoring of vital organ function. There is no specific antidote for this combination product.

When Immediate Medical Help is Required

Seek emergency medical help immediately if any signs or symptoms of overdosage, or any unexpected, severe adverse effects (such as trouble breathing, extreme tiredness, or signs of liver problems like yellowing of the skin or eyes) occur. Do not wait for symptoms to worsen.

Advertisements

Therapeutic Uses of Aspen Lamzid

What Aspen Lamzid Treats: Main Uses and Benefits

Aspen Lamzid is a fixed-dose combination medication generally used as part of antiretroviral combination therapy to treat Human Immunodeficiency Virus (HIV) type 1 infection in adults and children who meet specific weight requirements. The therapeutic function of the medication is relevant for managing the amount of virus and supporting the body's natural defenses. This medication is used to help manage the amount of HIV in the blood. This core action contributes to a crucial therapeutic benefit by supporting the goal of virologic suppression, which may assist in slowing the advancement of the disease.

This medication is commonly used across conditions characterized by periods of heightened symptoms related to the virus. Key therapeutic areas include long-term management of HIV infection, serving as a component of Postexposure Prophylaxis (PEP), and for preventing mother-to-child transmission during pregnancy. This core therapeutic strategy supports the body's immune recovery, which plays a key role in supporting health maintenance and helping to mitigate the risk of serious opportunistic infections.


Quick Fact: Relief for Systemic Imbalance

Focus Benefit Provided
Symptom Category Symptoms related to systemic imbalance affecting the immune system.
Clinical Scenario Applied in clinical settings that involve chronic, unstable symptom patterns and conditions marked by increased physiological stress.
Patient Benefit Contributes to improved comfort and assists with maintaining functional stability during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Aspen Lamzid?

Eligibility for Aspen Lamzid, a fixed-dose combination of lamivudine and zidovudine, is determined by specific regulatory criteria addressing patient demographics and pre-existing medical conditions.


Populations for Whom Use is Contraindicated

Use is contraindicated in patients with a history of hypersensitivity to Lamivudine or Zidovudine. Additionally, due to the Zidovudine component, the medicine must not be used in patients with severe blood count abnormalities, specifically abnormally low neutrophil counts (e.g., less than 0.75 imes 10^9 cells/L) or very low haemoglobin levels (e.g., less than 7.5 g/dL), as documented in regulatory labeling.


Age-Related and Physiological Restrictions

Population Group Regulatory Status
Adults and Adolescents Recommended for individuals weighing at least 30 kg.
Pediatric Patients Not recommended for children weighing less than 30 kg, as the fixed-dose tablet cannot be adjusted.
Renal/Hepatic Impairment Not recommended for patients with reduced kidney function (creatinine clearance leq 50 mL/min) or hepatic impairment (liver disease), as they may require dose adjustments.
Pregnancy/Lactation Use of the components is documented for preventing maternal-fetal HIV transmission; however, breastfeeding is not recommended for HIV-infected mothers to avoid postnatal transmission.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aspen Lamzid (Lamivudine/Zidovudine) has officially documented interactions that are categorized by their potential for therapeutic redundancy, toxicity enhancement, and pharmacokinetic alteration.

Interaction Classification Interacting Product/Category Regulatory Mandate
Avoided Combinations Stavudine, Emtricitabine, or other Lamivudine- or Zidovudine-containing products Concomitant use is not recommended or should be avoided (due to antagonism or therapeutic duplication).
Toxicity Reinforcement Ribavirin, Interferon alfa, or Bone Marrow Suppressive Agents Coadministration is not advised or requires caution due to the potential to increase hematologic or hepatic toxicity.
Exposure Modification Trimethoprim (component of Trimethoprim/Sulfamethoxazole) Increases Lamivudine exposure (AUC) by up to 43% by inhibiting renal transporters (OCT2/MATE1).
Product-Related Restriction Medicines containing Sorbitol Chronic coadministration should be avoided when possible due to officially documented dose-dependent reductions in Lamivudine exposure.

Due to the nature of this fixed-dose tablet, the official label specifies constraints related to dosage adjustment. The fixed combination is not recommended for patients with severe renal impairment (creatinine clearance le 50 mL/min) or severe hepatic impairment, as necessary dosage adjustments for the component drugs cannot be achieved with this single tablet formulation. In these cases, separate preparations of Lamivudine and Zidovudine must be used.

Advertisements

Mechanism of Action

How Aspen Lamzid Works

Aspen Lamzid operates via specific enzymatic inhibition to disrupt the target virus's replication machinery. The drug's components are designed to be converted into their active triphosphate forms by host cell enzymes after cellular uptake. These active molecules act as nucleoside analogs, structurally mimicking the natural building blocks required for genetic synthesis.

The core mechanism involves competitive binding to the viral enzyme reverse transcriptase. When the active drug is incorporated by this enzyme into the growing viral genetic strand, it immediately causes DNA chain termination. This molecular event prevents the reverse transcriptase from completing the necessary conversion of viral RNA into DNA. The resulting faulty genetic code limits the ability of new viral particles to be produced, initiating a cascade that results in a reduction in the rate of viral replication and a decrease in the overall circulating viral load.

Advertisements

Dosage and Administration Information

How to Use Aspen Lamzid

Aspen Lamzid is a fixed-dose combination medication for oral administration only. It is intended for long-term, continuous use as a core component of combination antiretroviral therapy (ART). The medication's administration pattern is highly standardized based on the specific composition of the tablet.


Standard Dosing and Administration Schedule

The standard regimen for adults and adolescents weighing at least 30 kg is one fixed-dose tablet (containing 150 mg Lamivudine and 300 mg Zidovudine) taken twice daily. This schedule is designed to maintain consistent drug levels and is typically adhered to at approximately 12-hour intervals. The tablet may be taken with or without food.

To ensure proper dosing, the tablet should be swallowed whole. If the tablet cannot be swallowed, official guidance allows it to be crushed and mixed with a small amount of liquid or semi-solid food, which must then be consumed immediately to receive the full dose.


Usage Constraints and Adjustments

Because Aspen Lamzid is a fixed-dose product, it cannot be adjusted to change the amount of Lamivudine or Zidovudine independently. This constraint defines its usage limits in clinical practice:

  • Renal or Hepatic Impairment: The tablet is not recommended for patients who require dose reduction, such as those with severe liver impairment or reduced kidney function (creatinine clearance le 50 mL/min). For these patients, Lamivudine and Zidovudine must be prescribed as separate component formulations to permit individualized dose adjustment.
  • Pediatric Use: The tablet is generally not recommended for children weighing less than 30 kg.
  • Missed Doses: If a dose is missed, it should be taken as soon as it is remembered, unless it is close to the time for the next dose; in that scenario, the missed dose is typically skipped.
Advertisements

Recent Clinical Evidence

Evidence Supporting Long-Term HIV-1 Management

Research for long-term HIV management relies on Randomized Controlled Trials (RCTs) and systematic reviews. Studies examined changes in viral load and CD4+ T-cell counts in treatment-naïve adults, comparing the dual-drug foundation to single-drug regimens or placebo. Findings described the documentation of suppressed plasma HIV RNA and monitored patterns related to CD4+ T-cell counts. Researchers monitor how the virus may develop genetic changes over time associated with reduced responsiveness. Certainty remains low regarding the direct comparison of this dual-drug regimen against the newer, more complex regimens, and some initial trials had limited follow-up durations.


Evidence for Preventing Mother-to-Child Transmission

Clinical trials and large observational cohort studies have evaluated the use of the component drugs for preventing viral transmission from mother to child. Primary outcomes included the HIV infection status of the child and the mother’s viral load levels. Studies observed patterns related to the rate of viral transmission. However, the virologic performance of this combination, when used as a dual-therapy regimen, is an area of ongoing research compared to what has been observed in studies of current three-drug regimens.


Evidence in Short-Term Prophylaxis

Research has explored the use of the combination as a backbone for short-term Postexposure Prophylaxis (PEP). Studies monitored the patient’s rate of regimen completion and the seroconversion rate (infection status) following exposure. Clinical trials reported the combination was frequently used as the foundation in three-drug PEP regimens. A key limitation is that data directly concerning the fixed-dose combination product as a stand-alone regimen are often derived from trials where a third agent was supplemented.


Long-Term Evidence and Durability of Response

Outcomes beyond short-term RCTs are explored through long-term observational cohort designs, which allow researchers to continue monitoring patients over several years. This research contributes to understanding how viral load may evolve over an extended duration and highlights the development of resistance patterns. It is important to understand that certainty remains low for outcomes beyond a few years because the initial RCTs, which provide the highest level of evidence, had limited follow-up durations.


Research Gaps and Areas of Uncertainty

Despite the extensive research base, certain areas of uncertainty remain, including the direct comparison of this combination against currently preferred treatment strategies. Data for certain special groups, such as older adults with HIV, remain insufficient. The follow-up durations for many initial trials were limited, meaning more research is ongoing to further explore long-term outcomes. This evidence highlights what is known—and what is still uncertain—about this foundational treatment.

Key Studies & References

  1. COMBIVIR (lamivudine and zidovudine tablet) Labeling Information (NIH/DailyMed)
  2. Lamivudine-Zidovudine Combination for Prevention of Maternal-Infant Transmission of HIV-1 (Study comparing combination to Zidovudine prophylaxis)
  3. WHO Recommendations on Post-Exposure Prophylaxis (PEP) Guidelines (Used to establish dual NRTI as a historical backbone)
  4. Lamivudine/Zidovudine Teva, INN-lamivudine/zidovudine (European Medicines Agency/Community Register Public Assessment Report)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Aspen Lamzid (FAQ)

Q: Can Aspen Lamzid be taken with over-the-counter pain relievers like ibuprofen?

Regulatory documents state that caution may be necessary when combining one of the components of Aspen Lamzid (zidovudine) with over-the-counter pain relievers like ibuprofen. This is due to the potential for an increased risk of bleeding. Official product information emphasizes that all nonprescription medicines should be disclosed to a healthcare professional.

Q: Are there any specific foods or drinks that should be avoided while using Aspen Lamzid?

Official guidance confirms that Aspen Lamzid may be taken with or without food. However, regulatory documents advise avoiding chronic coadministration with medicines or products containing the ingredient sorbitol due to its potential to reduce drug exposure. No specific foods are listed for avoidance.

Q: Does Aspen Lamzid cause fatigue or difficulty sleeping?

Official product information indicates that common side effects can include general fatigue and malaise. Difficulty falling asleep or staying asleep, also known as insomnia, is also listed among the frequently reported adverse reactions.

Q: Does Aspen Lamzid have any known effects on weight gain or loss?

Studies and official information suggest that Aspen Lamzid may be associated with changes in body fat distribution, a condition known as lipoatrophy, which often results in the loss of fat from the face, limbs, or buttocks. Unexplained weight loss has also been reported, while increased weight has been noted in the context of general antiretroviral therapy.

Q: Are there any specific vitamins or supplements that interact with Aspen Lamzid?

Official patient counseling information emphasizes the need to inform a healthcare professional about all prescription and nonprescription medications, as well as any vitamins, nutritional supplements, or herbal products being taken. The purpose of disclosure is to allow for proper monitoring and assessment of potential dosage adjustments.

Q: What should I do if I experience a very minor side effect from Aspen Lamzid?

Official patient counseling information advises informing a doctor or pharmacist if any side effects are severe or do not go away over time. For symptoms that may indicate a serious adverse event, regulatory information advises urgent contact with a healthcare professional.

Q: What does the term 'contraindication' mean in the context of Aspen Lamzid?

According to the official product information, a contraindication is a specific health status or pre-existing condition that makes using the medicine unsafe or inadvisable for a patient. For Aspen Lamzid, this includes a known severe allergy to the drug or specific, abnormally low blood counts.

Q: Is it possible for Aspen Lamzid to cause problems with vision?

Vision problems are not listed among the most common or frequently reported side effects. However, the regulatory label advises contacting a healthcare provider immediately if new or worsening symptoms, including any vision problems, develop during treatment.

Q: Can men and women expect different side effects from Aspen Lamzid?

Regulatory warnings indicate that the serious adverse reactions of lactic acidosis and liver toxicity may be more common in female patients or those who are very overweight. Beyond these specific, rare warnings, side effect incidence is generally not stratified by sex in the official patient information.

Q: Are there any common misuses of Aspen Lamzid that patients should know about?

Regulatory patient counseling materials indicate that misuse includes not following the exact directions for taking the medicine or stopping treatment without professional consultation. Stopping the medication could lead to serious health consequences, such as the worsening of HIV or Hepatitis B.

Q: Does Aspen Lamzid interact with common herbal supplements like St. John's Wort?

While St. John’s Wort is not specifically listed as an interaction for this combination, official patient counseling materials advise informing a healthcare professional about all herbal products taken. This allows the doctor to monitor for any potential changes in drug effect or possible interactions.

Q: How long does Aspen Lamzid stay in the body after the last dose?

Pharmacokinetic data indicates that one of the active ingredients, Zidovudine, has a short half-life of approximately one hour in the blood plasma. However, the drug’s active form remains trapped inside the body's cells for longer, with an intracellular half-life of about seven hours.

Q: Does Aspen Lamzid impact mood or emotional state?

Official reports from clinical studies indicate that side effects can include changes in mood or emotional state, specifically depressive disorders. If a patient notices any concerning changes in their emotional well-being, they are advised to inform a healthcare professional.

Q: Is Aspen Lamzid a brand name or a generic name?

The name Lamivudine and Zidovudine is the generic name for this fixed-dose product. Aspen Lamzid is the name under which it is marketed, while the original brand name for this specific combination was Combivir®.

Q: What is the purpose of the different strengths (dosage options) of Aspen Lamzid?

Official product information indicates that different strengths or preparations of the drug are available, primarily to allow for weight-based dose adjustments. This is most relevant for use in children and adolescents who are under the 30 kg weight limit for the standard tablet.

Q: Does regulatory information mention any risks related to driving or operating machinery?

Official product information for the component drugs states that no specific studies have been performed to assess the effects of the medication on a person's ability to drive or use machinery. Patients should be aware of any side effects that could affect their concentration or reaction time.

Q: How does Aspen Lamzid get eliminated from the body?

Official pharmacokinetic data describes that the active ingredients are primarily eliminated by the kidneys. Lamivudine is mostly excreted as the unchanged drug, while Zidovudine is largely eliminated in the urine as an inactive metabolite.

Q: Does the package insert include a patient information leaflet?

Official regulatory guidance confirms that the package insert includes a patient information leaflet. Patients are advised to request a copy of this official manufacturer's leaflet or the prescribing information from their pharmacist or doctor.

Q: Is there a risk of dependency or withdrawal when stopping Aspen Lamzid?

Official warnings indicate there is no known risk of dependency with this medication. However, if a patient is co-infected with Hepatitis B, abruptly stopping treatment may cause an acute and severe exacerbation of the Hepatitis B infection. Official guidance stresses that treatment cessation should only occur under the direction and supervision of a healthcare professional.

Q: Can Aspen Lamzid affect the results of common lab tests?

According to the official label, the drug can affect the results of common laboratory tests due to its association with hematologic toxicity, such as severe anemia and neutropenia. This effect is why periodic monitoring of blood counts, liver enzymes, and lipid levels may be conducted.

Q: Is Aspen Lamzid safe to use during pregnancy or while breastfeeding?

Official documentation confirms that the component drugs have been evaluated for use during pregnancy, specifically to prevent mother-to-child transmission. However, due to the risk of postnatal viral transmission, breastfeeding is not recommended for mothers living with HIV.

Q: What kind of warnings are included in the official prescribing information for Aspen Lamzid?

The official prescribing information includes several prominent Boxed Warnings from regulatory agencies. These warnings highlight the potential for serious conditions, including Lactic Acidosis, severe Hepatomegaly with Steatosis (liver enlargement), Hematologic Toxicity, and Myopathy (muscle disease).

Q: Are there any specific warning signs that indicate a side effect is becoming serious?

Official patient guidance advises patients to monitor for specific warning signs that might indicate a serious side effect. These signs include unusual tiredness, pale skin, unexplained muscle weakness or pain, yellowing of the skin or eyes, or shortness of breath.

Q: Is Aspen Lamzid used as a first-line treatment or usually after other options fail?

Regulatory clinical trial data indicates that the drug is evaluated as a foundational regimen used in combination with other antiretroviral agents. This use, often in treatment-naïve adult patients, is consistent with its role as a core component in the current standard of care.

Advertisements

How should Aspen Lamzid be stored and disposed of?

How to Store and Dispose of Aspen Lamzid

Aspen Lamzid (lamivudine/zidovudine) must be stored strictly according to regulatory specifications to maintain its stability and ensure safety.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically between 68 F and 77 F (20 C and 25 C).
Protection Keep protected from freezing, excessive heat, moisture, and direct light.
Container Keep the medicine in its original container, tightly closed, and out of the sight and reach of children.

Disposal Instructions

Do not keep tablets that are outdated or no longer needed. Patients are required to ask a healthcare professional or follow official local guidelines for the proper disposal of any unused medication. Do not flush the product unless specifically instructed to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aspen Lamzid found in:

A-Z Index: